A Phase 4 interventional study of AI-POCUS (BabyChecker, Delft Imaging) and AI-POCUS (Edan, China) in Pregnancy, Pregnancy Complications and Preterm Birth, sponsored by Tsinghua University. Not yet recruiting at 1 site in Ethiopia. Open to female participants aged 15 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Tsinghua University · Phase 4, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Maternal and neonatal health remains one of the most pressing global health challenges, particularly in low- and middle-income countries (LMICs). Ethiopia continues to face a high burden, with maternal mortality estimated at 195 per 100,000 live births, neonatal mortality at 27 per 1,000 live births, and perinatal mortality rates ranging from 37‰ to 124‰ depending on the level of care. These outcomes remain substantially higher than the targets set under the United Nations Sustainable Development Goals (SDGs) for 2030.
The World Health Organization (WHO) recommends that all pregnant women receive at least one ultrasound scan before 24 weeks of gestation, yet nearly two-thirds of women worldwide-especially in LMICs-lack access to this service. Barriers include high costs of ultrasound machines, limited technical expertise, and shortages of skilled sonographers in rural primary care.
Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) represents a promising innovation to expand prenatal imaging in resource-constrained settings by equipping frontline health workers with AI-supported diagnostic capabilities. This study, conducted under the Tsinghua University BRIGHT (Bringing Research to Impact for Global Health at Tsinghua) program, will evaluate the clinical effectiveness, feasibility, cost, and scalability of AI-POCUS in rural Ethiopia. A three-arm cluster randomized controlled trial will compare two AI-enabled ultrasound technologies-BabyChecker (Netherlands) and a China-developed AI-POCUS device-against standard antenatal care without ultrasound. Findings will generate robust clinical and policy-relevant evidence to guide the sustainable implementation of AI-enabled maternal health interventions in sub-Saharan Africa.
Maternal and neonatal morbidity and mortality remain unacceptably high in sub-Saharan Africa and continue to impede progress toward global health targets. In Ethiopia, recent estimates show maternal mortality at 195 per 100,000 live births and neonatal mortality at 27 per 1,000 live births. Perinatal mortality is also elevated, ranging between 66‰ and 124‰ in hospital-based settings and 37‰ to 52‰ in community-level health facilities. These figures surpass the Sustainable Development Goal (SDG) thresholds for 2030, underscoring the urgent need for innovative, scalable solutions.
Ultrasound imaging is a cornerstone of modern antenatal care. The WHO recommends at least one ultrasound before 24 weeks' gestation to assess gestational age, detect multiple pregnancies, identify fetal anomalies, and diagnose high-risk conditions such as preeclampsia, placenta previa, or growth restriction. However, nearly two-thirds of pregnant women worldwide still lack access to this basic diagnostic tool. In low-resource environments, the barriers include limited infrastructure, high equipment costs, technical complexity, and the scarcity of trained professionals capable of performing and interpreting scans. As a result, potentially preventable maternal and neonatal deaths remain common.
Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) introduces a transformative opportunity to address these gaps. POCUS devices embedded with AI algorithms can guide non-specialist health workers in image acquisition and interpretation, reducing reliance on highly trained personnel and lowering barriers to integration within primary care. Such innovations may strengthen early detection of pregnancy complications, enable timely referral to higher-level care, and ultimately improve maternal and neonatal survival.
This study is embedded within the Bringing Research to Impact for Global Health at Tsinghua (BRIGHT) initiative. It will use a three-arm cluster randomized controlled trial (C-RCT) design to evaluate and compare: (1) BabyChecker, a portable AI-enabled ultrasound developed in the Netherlands, (2) A China-developed AI-POCUS device, and (3) Standard antenatal care (ANC) without ultrasound, reflecting current practice in many rural Ethiopian communities.
The study population will include pregnant women receiving antenatal care in rural Ethiopia, as well as primary health care providers delivering these services. Data will be collected at both the patient and facility level to capture maternal and neonatal health outcomes, health service utilization, and system-level performance indicators.
Evaluation will follow a multi-dimensional framework, addressing:
The study aims to provide rigorous clinical evidence and practical implementation guidance on how AI-POCUS technologies can be sustainably scaled in resource-constrained settings. Findings are expected to inform national health policies, guide investment decisions, and offer a replicable model for expanding maternal health technologies across sub-Saharan Africa and other LMICs.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
This study's planned enrollment of 1,059 is above the median of 144 across 205 interventional studies indexed under Pregnancy Complications.
Browse Pregnancy Complications studies →Tsinghua University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive routine antenatal care (ANC) according to Ethiopian national guidelines, without the use of AI-POCUS devices. All examinations, screenings, and referrals will be conducted through standard clinical practice. This group serves as the baseline comparator for evaluating the added impact of AI-POCUS technology.
Health centers in this arm will be equipped with the BabyChecker system developed by Delft Imaging (Netherlands). The portable device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, and provides diagnostic suggestions and risk alerts. After brief training, primary healthcare workers will independently perform antenatal examinations, screen for obstetric complications, and make referral decisions.
Device: AI-POCUS (BabyChecker, Delft Imaging)
This arm will use the AI-POCUS device developed by Edan (China), designed to analyze blind ultrasound sweeps and automatically extract fetal diagnostic parameters. The system supports the early detection of maternal and fetal risks and assists in clinical decision-making.
Device: AI-POCUS (Edan, China)
A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
Maternal Mortality Ratio
Maternal deaths per 100,000 live births, defined as deaths occurring during pregnancy or within 42 days postpartum due to pregnancy-related causes.
Time frame: Baseline through 42 days postpartum
Stillbirth Rate / Perinatal Mortality Rate
Stillbirths (≥28 weeks gestation) per 1,000 total births, and perinatal mortality including stillbirths and neonatal deaths within the first 7 days of life.
Time frame: Delivery through 7 days postpartum
Early Neonatal Mortality Rate
Neonatal deaths within the first 7 days of life per 1,000 live births.
Time frame: Birth through 7 days postpartum
Preterm Birth Rate
Proportion of births before 37 completed weeks of gestation, subdivided into extremely preterm (\<32 weeks), very preterm (32-33 weeks), and late preterm (34-36 weeks).
Time frame: At delivery
Maternal and Neonatal Referral Rate
Proportion of mothers or newborns referred to higher-level hospitals due to severe complications.
Time frame: Antenatal period through 42 days postpartum
Congenital Anomaly Rate
Proportion of infants with major structural anomalies detected by prenatal ultrasound or confirmed postnatally (e.g., neural tube defects, limb malformations, cleft lip/palate).
Time frame: Antenatal period through delivery
Completion of ≥4/8 Antenatal Care (ANC) Visits
Proportion of pregnant women who completed at least 4 of 8 ANC visits, respectively, during pregnancy, according to WHO recommendations.
Time frame: Pregnancy through delivery
High-Risk Pregnancy Detection Rate
Proportion of pregnant women identified as high-risk (e.g., placenta previa, malpresentation) by AI-POCUS or conventional ultrasound, divided by total enrolled women.
Time frame: Pregnancy through delivery
High-Risk Pregnancy Follow-Up Completion Rate
Among women identified as high-risk, proportion who completed at least 1 or 2 follow-up ANC visits.
Time frame: Pregnancy through delivery
Referral Completion Rate After Screening
Proportion of women meeting high-risk pregnancy criteria who successfully completed referral to a higher-level hospital.
Time frame: Pregnancy through delivery
Plan to share: Undecided — Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Mar 2026, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tsinghua University